Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NCT07218913
Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors
- NCT07218913 ↗
- Recruiting
- City of Hope Medical Center
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Phase 1 Trial of Pedmark in Men Receiving Cisplatin for Metastatic Germ Cell Tumor
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Hearing Loss; Metastatic Malignant Germ Cell Tumor; Metastatic Malignant Nongerminomatous Germ Cell Tumor; Metastatic Malignant Testicular Non-Seminomatous Germ Cell Tumor; Metastatic Testicular Seminoma; Stage II Testicular Cancer AJCC v8; Stage III Testicular Cancer AJCC v8
- Interventions
- Audiometric Test; Cisplatin; Computed Tomography; Magnetic Resonance Imaging; Sodium Thiosulfate Anhydrous
- Arms
- Arm I (SOC cisplatin) · Active comparator
- Arm II (SOC cisplatin, Pedmark) · Experimental
- Enrollment
- 44 (estimated)
- Primary outcomes
- Incidence of clinically meaningful ototoxicity
- Sponsor
- City of Hope Medical Center with National Cancer Institute (NCI)
- Start
- Feb 19, 2026
- Primary completion
- Jan 22, 2031 (estimated)
- Results posted
- No
- Registry record
- NCT07218913 · updated Apr 17, 2026